| Literature DB >> 35011829 |
Anna Polewczyk1,2, Wojciech Jacheć3, Dorota Nowosielecka4, Andrzej Tomaszewski5, Wojciech Brzozowski5, Dorota Szczęśniak-Stańczyk5, Krzysztof Duda6, Andrzej Kutarski6.
Abstract
BACKGROUND: Lead-related tricuspid valve dysfunction (LDTVD) has not been studied in a large population and its management remains controversial.Entities:
Keywords: improvement of tricuspid valve function; lead dependent tricuspid valve dysfunction; prognosis; transvenous lead extraction
Year: 2021 PMID: 35011829 PMCID: PMC8745716 DOI: 10.3390/jcm11010089
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Basic information about 119 patients with confirmed LDTVD.
|
|
| ||||
| Preliminary diagnosis of LDTVD | 125 | 4.90% | Insignificant | 73 | 61.34% |
| Confirmed diagnosis of LDTVD | 119 | 4.44% | Perceptible | 33 | 27.73% |
| All patients | 2678 | 100.00% | Significant | 13 | 10.92% |
|
| All LDTVD patients | 119 | 100.00% | ||
| Symptomatic lead dependent TV dysfunction | 45 | 37.82% | |||
| Lead damage/dysfunction (lead replacement) | 39 | 32.78% |
| ||
| Systemic infection or local or mixed infection | 21 | 17.65% | No change (the same) | 77 | 64.71% |
| Upgrading, downgrading, prevention of lead abandonment | 11 | 9.24% | Reduction of TR for 1 degree | 38 | 31.93% |
| Recapture venous access (symptomatic occlusion, lead replacement/upgrading) | 3 | 2.52% | Reduction of TR for 2 degrees | 4 | 3.36% |
| All LDTVD patients | 119 | 100.00% | All LDTVD patients | 119 | 100.00% |
|
| Average right ventricular lead dwell time | 104.57 | SD 69.8 | ||
| Propping upward the leaflet by the lead | 45 | 37.82% |
| ||
| Drawing down f the leaflet by the lead (immobilisation) | 57 | 47.90% | Indication reached—observation | 22 | 18.49% |
| Impingement of the leaflet by the lead presence (irritation) | 3 | 2.52% | No indication—observation only | 74 | 62.19% |
| Perforation of the leaflet with the lead | 3 | 2.52% | Referred for TV plastic | 18 | 15.13% |
| Connection of lead with the lead with scar | 11 | 9.24% | Not considered (contraindication, lack of agreement) | 5 | 4.20% |
| All LDTVD patients | 119 | 100.00% | ALL patients with LDTVD | 119 | 100.00% |
Abbreviations: LDTVD—lead dependent tricuspid valve dysfunction, TLE—transvenous lead extraction, TV—tricuspid valve, TR- tricuspid regurgitation.
Clinical data-classification according to the occurrence of LDTVD.
| Patient-Related Potential Risk Factors of LDTVD | LDTVD (All Patients with LDTVD) | NO LDTVD (Control Group) | |||
|---|---|---|---|---|---|
| Number of patients/number of the group | 119 | 1 | 2559 | 2 |
|
| Presented values | Count/average | %/Sd | Count/average | %/Sd | 1 vs. 2 |
| Patient’s age during TLE | 68.09 | 15.05 | 66.90 | 14.52 | 0.087 |
| Patient’s age during first system implantation | 58.43 | 18.96 | 58.32 | 16.18 | 0.485 |
| Sex (% of female patients) | 67 | 56.30% | 995 | 38.88% | 0.001 |
| Baseline heart diseases: IHD, MI | 69 | 57.98% | 1494 | 58.38% | 0.995 |
| Baseline heart diseases: primary cardiomyopathy | 13 | 10.92% | 343 | 13.40% | 0.562 |
| Baseline heart diseases: valvular heart disease | 10 | 8.40% | 59 | 2.31% | 0.001 |
| Baseline heart diseases: post-inflammatory, congenital, channelopathies, neurocardiogenic, unknown | 27 | 22.69% | 662 | 25.87% | 0.566 |
| NYHA class I–IV | 2.20 | 0.80 | 1.84 | 0.67 | <0.001 |
| AF permanent | 50 | 42.02% | 565 | 22.08% | 0.001 |
| Hypertension | 66 | 55.46% | 1487 | 58.11% | 0.777 |
| Diabetes (any) | 21 | 17.65% | 534 | 20.87% | 0.515 |
| Renal failure (any) | 34 | 28.57% | 538 | 21.02% | 0.052 |
| Valvular implant presence | 83 | 18.49% | 156 | 6.10% | 0.001 |
| Mechanical valve presence | 15 | 12.61% | 15 | 3.59% | 0.001 |
| Previous sternotomy | 24 | 20.17% | 359 | 14.03% | 0.07 |
| Long-term anticoagulation | 73 | 61.35% | 1000 | 39.08% | 0.001 |
| Charlson’s index (points) | 4.99 | 3.56 | 4.83 | 3.69 | 0.352 |
Abbreviations: AF—atrial fibrillation, IHD—ischaemic heart disease, MI—myocardial infarction, LDTVD—lead dependent tricuspid valve dysfunction, NYHA class—New York Hear Association class, TLE—transvenous lead extraction. Valvular implant: mechanical valve, biological valve, mitral o tricuspid ring.
Indication, system and history of pacing -related factors. Classification according to the occurrence of LDTVD.
| LDTVD (All Patients with LDTVD) | NO LDTVD (Control Group) | ||||
|---|---|---|---|---|---|
| Number of Patients Number of the Group | 119 | 1 | 2559 | 2 |
|
| Presented Values | Count/Average | %/ Sd | Count/Average | %/Sd | 1 vs. 2 |
|
| |||||
| LRIE certain with or without pocket infection | 13 | 10.92% | 458 | 17.90% | 0.078 |
| LRIE probable with or without pocket infection | 4 | 3.36% | 159 | 6.21% | 0.279 |
| Local/isolated pocket infection | 4 | 3.36% | 206 | 8.05% | 0.099 |
| All infections | 21 | 17.65% | 823 | 32.16% | 0.002 |
| Non-infectious prophylactic indications | 5 | 4.20% | 86 | 3.36% | 0.788 |
| Non-infectious therapeutic indications | 93 | 78.15% | 1650 | 64.48% | 0.002 |
| All non-infectious indications | 98 | 82.35% | 1736 | 67.84% | 0.001 |
|
| |||||
| Device type—PM (AAI, VVI, DDD, CRT-P) | 100 | 84.03% | 1786 | 69.79% | 0.001 |
| Device type—ICD (VVI, DDD) | 9 | 7.56% | 577 | 22.55% | 0.001 |
| Device type—CRT-D | 10 | 8.40% | 196 | 7.66% | 0.865 |
| Number of leads in the system before TLE | 1.84 | 0.70 | 1.82 | 0.62 | 0.971 |
| Presence of abandoned lead before TLE | 16 | 13.45% | 270 | 10.55% | 0.363 |
| Number of abandoned leads before TLE | 0.21 | 0.60 | 0.14 | 0.43 | 0.636 |
| Number of leads in the heart before TLE | 2.03 | 0.82 | 1.95 | 0.73 | 0.459 |
| 4 and >4 leads before TLE | 7 | 5.88% | 73 | 2.85% | 0.096 |
| One ICD lead before TLE | 18 | 15.13% | 762 | 29.78% | 0.001 |
| 2 or more ICD leads before TLE | 2 | 1.68% | 18 | 7.03% | 0.493 |
| Apical RV lead location (lead analysis) | 101 | 41.91% | 2058 | 41.39% | 0.166 |
| Out of apical (septal, outfow tract, anterior wall) RV lead location (lead analysis) | 30 | 12.45% | 483 | 9.71% | 0.092 |
| Previous TLE in history | 8 | 6.72% | 135 | 5.28% | 0.603 |
| Upgrading or downgrading with lead abandonment | 11 | 9.24% | 158 | 6.17% | 0.229 |
| Excessive long lead loop in the atrium (fluoroscopy) | 18 | 15.13% | 311 | 12.15% | 0.374 |
| Excessive lead loop crossing TV or in the ventricle (fluoroscopy)—A | 24 | 20.17% | 116 | 4.53% | 0.001 |
| Fluoroscopic impression of lead collision with TV (without loop) to tense or to long—B | 25 | 21.01% | 15 | 0.59% | 0.001 |
| Fluoroscopic impression of lead loop collision with TV—C | 25 | 21.01% | 115 | 4.49% | 0.001 |
| All lead’s collision with TV (A + B + C) | 74 | 62.19% | 246 | 9.61% | 0.001 |
| Dwell time of oldest one lead in the patient before TLE | 116.82 | 81.90 | 103.73 | 75.64 | 0.106 |
| Mean lead dwell time (in the patient) before TLE (in months) | 107.73 | 68.90 | 95.83 | 66.98 | 0.058 |
Abbreviations: CRT—cardiac resynchronization therapy, ICD—implantable cardioverter defibrillator, LRIE—lead related infective endocarditis, MI—myocardial infarction, LDTVD—lead dependent tricuspid valve dysfunction, PM—pacemaker, RV—right ventricle, TLE—transvenous lead extraction, TV—tricuspid valve.
TLE procedure complexity, efficacy, complications, outcomes and long-term mortality after TLE. Classification according to the occurrence of LDTVD.
| TLE Procedure Complicity, Efficacy, Complications, Outcomes and Long-Term Mortality after TLE | LDTVD (All Patients with LDTVD) | NO LDTVD (Control Group) | |||
|---|---|---|---|---|---|
| Number of Patients Number of the Group | 119 | 1 | 2559 | 2 |
|
| Presented Values | Count/Average | %/Sd | Count/Average | %/Sd | 1 vs. 2 |
|
| |||||
| Procedure duration (sheath to sheath) | 29.66 | 35.90 | 14.44 | 21.60 | 0.242 |
| Average time of single lead extraction (sheath-to sheath/number of extracted leads) | 11.05 | 17.24 | 8.64 | 12.03 | 0.512 |
| Technical problem during TLE (any) | 29 | 24.37% | 531 | 20.75% | 0.356 |
| Number of big technical problems | 1.71 | 1.15 | 1.34 | 0.65 | 0.153 |
| One technical problem only | 16 | 13.45% | 322 | 12.58% | 0.842 |
| Two or more technical Problems | 12 | 10.08% | 113 | 4.42% | 0.007 |
|
| |||||
| Evolution (old and new) or TighRail | 6 | 5.04% | 38 | 1.49% | 0.008 |
| Lasso catheter/snare | 9 | 7.56% | 94 | 3.67% | 0.050 |
| Basket catheter | 1 | 0.84% | 19 | 0.74% | 0.683 |
|
| |||||
| Major complications (any) | 1 | 0.84% | 50 | 1.95% | 0.613 |
| Hemopericardium | 1 | 0.84% | 28 | 1.09% | 0.834 |
| Haemothorax | 0 | 0.00% | 3 | 0.31% | 0.298 |
| Tricuspid valve damage (significant) during TLE | 0 | 0.00% | 17 | 0.66% | 0.771 |
| Rescue cardiac surgery | 0 | 0.00% | 23 | 0.90% | 0.604 |
| Minor complications (any) | 14 | 11.76% | 204 | 7.98% | 0.172 |
| Death procedure related (intra, post-procedural) | 0 | 0.00% | 0 | 0.00% | N |
| Death indication-related (intra, post-procedural) | 0 | 0.00% | 1 | 0.04% | 0.026 |
| Partial radiological success (remained tip or < 4 cm lead fragment) | 10 | 8.40% | 93 | 3.63% | 0.014 |
| Full clinical success | 118 | 99.16% | 2504 | 97.85% | 0.17 |
| Full procedural success | 108 | 90.76% | 2446 | 95.58% | 0.191 |
|
| |||||
| Alive during 1658 ± 1203 (1–5519) days of follow up | 78 | 65.55% | 1796 | 70.18% | 0.329 |
| Death during all 1658 ± 1203 (1–5519) days of follow up | 41 | 34.45% | 763 | 29.82% | 0.329 |
Abbreviations: LDTV—lead dependent tricuspid valve dysfunction, TLE—transvenous lead extraction.
Echocardiographic findings/abnormalities. Classification according to the occurrence of LDTVD.
| Echocardiographic Findings/Abnormalities Recorded in Patients with or without LDTVD | LDTVD (All Patients with LDTVD) | NO LDTVD (Control Group) | |||
|---|---|---|---|---|---|
| Number of Patients Number of the Group | 119 | 1 | 2559 | 2 |
|
| Presented Values | Count/Average | %/Sd | Count/Average | %/Sd | 1 vs. 2 |
|
| |||||
| Average LVEF | 48.58 | 13.27 | 49.53 | 15.46 | 0.153 |
| Mitral regurgitation (significant) | 24/112 | 21.43% | 352/2528 | 13.92% | 0.037 |
| PASP (mmHg) | 40.73 | 13.41 | 30.49 | 13.16 | 0.001 |
| RV diameter (mm) | 35.51 | 7.65 | 31.24 | 6.00 | 0.001 |
|
| |||||
| Non-significant (0, 1, 2 grade ) | 14/119 | 11.77% | 2123/2553 | 83.16% | 0.001 |
| Significant (3 grade) | 48/119 | 40.34% | 360/2553 | 14.10% | 0.001 |
| Severe (4 grade) | 57/119 | 47.90% | 70/2553 | 2.74% | 0.001 |
|
| |||||
| Any shadows on leads before TLE | 53/119 | 52.94% | 1264/2554 | 49.39% | 0.336 |
| Connecting tissue surrounding the lead | 7/119 | 5.88% | 262/2557 | 10.25% | 0.164 |
| Blood cloth on the lead | 11/119 | 9.24% | 164/2557 | 6.41% | 0.336 |
| Vegetation-like mass | 1/119 | 0.84% | 107/2557 | 4.18% | 0.116 |
| Thicker lead | 26/119 | 21.85% | 470/2557 | 18.38% | 0.406 |
| Vegetation | 16/119 | 13.45% | 450/2556 | 17.61% | 0.296 |
| Strong connective tissue scar connection of the lead with heart structures (any) | 28/115 | 24.35% | 315/2498 | 12.61% | 0.001 |
| Strong connective tissue scar connection of the lead with tricuspid apparatus | 17/119 | 14.29% | 124/2557 | 4.85% | 0.001 |
| Strong connective tissue scar connection of the lead with RA wall | 11/119 | 9.24% | 99/2557 | 3.87% | 0.008 |
| Strong connective tissue scar connection of the lead with SVC | 5/119 | 4.20% | 104/2557 | 4.07% | 0.869 |
| Strong connective tissue scar connection of the lead with RV wall | 14/119 | 11.77% | 157/2557 | 6.14% | 0.073 |
|
| |||||
| Excessive loops of the leads in the heart (any)/ECHO | 43/119 | 36.13% | 450/2558 | 17.59% | 0.001 |
| Excessive loop in the RA | 27/119 | 22.69% | 331/2558 | 12.94% | 0.001 |
| Excessive loop in the TV | 27/119 | 22.69% | 94/2558 | 2.68% | 0.001 |
| Excessive loop in the RV | 20/119 | 16.81% | 124/2558 | 4.85% | 0.001 |
Abbreviations: LVEF—left ventricular ejection fraction, LDTVD—lead dependent tricuspid valve dysfunction, PASP—pulmonary artery systolic pressure, RA—right atrium, RV—right ventricle, SVC—superior vena cava, TLE—transvenous lead extraction, TV—tricuspid valve.
Figure 1The excessive loop of the lead as a reason of LDTVD. (A): The loop of the atrial lead in the tricuspid valve (TV), entering the right ventricular (RV) lumen (yellow arrows). A ventricular lead through the TV forms a loop in the right ventricular outflow tract RVOT (red arrows). TEE 2D. (B): Three leads visible in the tricuspid valve, atrial loop of the lead distributed in the commissures (yellow arrows), centrally located ventricular lead (red arrow). TEE 3D. (C): After removal of the ventricular lead (TLE), the atrial lead loop was clearly visible. TEE 2D. (D): Two jets of a significant tricuspid regurgitation (TR) to the right atrium resulting from the collision of the three leads with the valve leaflets. TEE 3D color doppler. (E): The effect after TLE procedure. Two jets of non-significant tricuspid regurgitation remained. TEE 2D.
Factors connected with LDTVD presence. Results of uni- and multi-variable logistic regression analysis.
| 19 LDTVD vs. Other (2559) | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Patient’s age during TLE (by year) | 1.008 | 0.995–0.021 | 0.239 | |||
| Female gender | 1.927 | 1.327–1.797 | <0.001 | 2.441 | 1.514–3.937 | <0.001 |
| Baseline heart diseases: valvular heart disease | 3.248 | 1.860–1.669 | <0.001 | 2.755 | 1.153–6.580 | 0.022 |
| NYHA class (by 1) | 2.092 | 1.609–2.720 | <0.001 | 2.060 | 1.443–2.940 | <0.001 |
| PASP (by 1 mm Hg) | 1.047 | 1.035–1.060 | <0.001 | 1.030 | 1.014–1.046 | <0.001 |
| RV diameter (by 1 mm) | 1.099 | 1.073–1.126 | <0.001 | 1.079 | 1.043–1.116 | <0.001 |
| Permanent AF | 2.555 | 1.750–3.730 | <0.001 | 1.776 | 0.985–3.201 | 0.056 |
| Mitral valve insufficiency | 1.897 | 1.214–2.963 | 0.004 | 1.038 | 0.586–1.840 | 0.879 |
| Renal failure (any) | 1.447 | 0.956–2.191 | 0.081 | 1.058 | 0.631–1.773 | 0.831 |
| Valvular implant presence | 2.801 | 1.633–4.804 | <0.001 | 1.045 | 0.431–2.534 | 0.922 |
| Previous sternotomy | 1.377 | 0.855–2.216 | 0.187 | |||
| Long term anticoagulation | 2.254 | 1.547–3.284 | <0.000 | 1.152 | 0.634–2.092 | 0.643 |
| Presence of pacing leads only (AAI VVI VDD DDD CRTP) | 2.116 | 1.321–3.390 | 0.002 | 1.812 | 1.001–3.279 | 0.050 |
| Presence of HV lead(s) (without CRTD) | 0.406 | 0.238–0.693 | <0.001 | |||
| ≥4 leads before TLE | 1.848 | 0.788–4.334 | 0.158 | |||
| Mean lead dwell time before TLE (by year) | 1.030 | 0.999–1.063 | 0.062 | 0.969 | 0.925–1.015 | 0.184 |
| * Lead(s) collision with TV (including excessive loop (s) of lead (s)) | 12.765 | 8.506–19.16 | <0.001 | 15.283 | 9.101–25.663 | <0.001 |
| * Excessive loops of the leads in the heart (any)/ECHO | 2.790 | 1.878–4.143 | <0.001 | |||
| Excessive loop in the RA/ECHO | 2.031 | 1.290–3.197 | 0.002 | |||
| Excessive loop in the TV/ECHO | 7.630 | 4.701–12.385 | <0.001 | |||
| Excessive loop in the RV/ECHO | 4.034 | 2.382–6.830 | <0.001 | |||
| Strong connective tissue scar connection of the lead with heart structures (any) | 2.489 | 1.605–3.861 | <0.001 | |||
| Strong connective tissue scar connection of the lead with tricuspid apparatus | 3.397 | 1.938–5.954 | <0.001 | 2.004 | 0.958–4.196 | 0.065 |
| Strong connective tissue scar connection of the lead with RA wall | 2.934 | 1.520–5.663 | <0.001 | 3.601 | 1.639–7.912 | <0.001 |
| Strong connective tissue scar connection of the lead with RV wall | 2.313 | 1.289–4.151 | 0.005 | 2.151 | 0.992–4.663 | 0.052 |
* Due to the result of the two-factor regression analysis for the multivariate model, the variable “Lead (s) collision with TV (including excessive loop (s) of lead (s))” was selected, ignoring the change “excessive loops of the leads in the heart (any)/ECHO”. OR for “leads collision” = 14.942; p < 0.001 and OR for “excessive loops” = 0.750; p = 0.311. Abbreviations: AF—atrial fibrillation, CRT—cardiac resynchronization therapy, LDTVD—lead dependent tricuspid valve dysfunction, HV—high voltage lead, PASP—pulmonary artery systolic pressure, RA—right atrium, RV—right ventricle, TLE—transvenous lead extraction, TV—tricuspid valve.
Figure 2Kaplan–Meier curves of survival depending on the prevalence of LDTVD and changes after TLE.
Figure 3Tricuspid valve dysfunction with significant regurgitation as a result of an unfavorable interaction of the lead with the valve leaflet. Monitoring of the TLE procedure by TEE examination. (A): Septal leaflet is clamping down (blue arrow) by a ventricular lead (red arrow) with impaired coaptation of the tricuspid valve TEE 3D. (B): Severe tricuspid regurgitation as a consequence of pulling the leaflet. TEE 2D color Doppler valve. (C): Imaging after TLE. Improving the mobility of the septal leaflet and the coaptation zone (blue arrow). TEE 3D. (D): Significant improvement in the degree of valve regurgitation after extraction of the lead. TEE 2D.